{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:16:14Z","timestamp":1790252174515,"version":"4.1.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["U54GM115677"],"award-info":[{"award-number":["U54GM115677"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.biomaterials.2018.10.022","type":"journal-article","created":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T18:22:29Z","timestamp":1540059749000},"page":"48-59","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":108,"special_numbering":"C","title":["Gemcitabine nanoparticles promote antitumor immunity against melanoma"],"prefix":"10.1016","volume":"189","author":[{"given":"Yuan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Bush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingfang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin A.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biomaterials.2018.10.022_bib1","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nri3175","article-title":"Coordinated regulation of myeloid cells by tumours","volume":"12","author":"Gabrilovich","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biomaterials.2018.10.022_bib2","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","article-title":"The nature of myeloid-derived suppressor cells in the tumor microenvironment","volume":"37","author":"Kumar","year":"2016","journal-title":"Trends Immunol."},{"key":"10.1016\/j.biomaterials.2018.10.022_bib3","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biomaterials.2018.10.022_bib4","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/ijc.28449","article-title":"Enhanced suppressive capacity of tumor-infiltrating myeloid-derived suppressor cells compared with their peripheral counterparts","volume":"134","author":"Maenhout","year":"2014","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.biomaterials.2018.10.022_bib5","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1158\/0008-5472.CAN-07-6621","article-title":"Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells","volume":"68","author":"Serafini","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.biomaterials.2018.10.022_bib6","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1158\/0008-5472.CAN-05-1299","article-title":"Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host","volume":"66","author":"Huang","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.biomaterials.2018.10.022_bib7","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/gutjnl-2016-312078","article-title":"Myeloid cells are required for PD-1\/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer","volume":"66","author":"Zhang","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.biomaterials.2018.10.022_bib8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fonc.2013.00049","article-title":"Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer","volume":"3","author":"Najjar","year":"2013","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biomaterials.2018.10.022_bib9","doi-asserted-by":"crossref","first-page":"6713","DOI":"10.1158\/1078-0432.CCR-05-0883","article-title":"Gemcitabine selectively eliminates splenic Gr-1+\/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity","volume":"11","author":"Suzuki","year":"2005","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.biomaterials.2018.10.022_bib10","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.intimp.2009.03.015","article-title":"Gemcitabine directly inhibits myeloid derived suppressor cells in BALB\/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice","volume":"9","author":"Le","year":"2009","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.biomaterials.2018.10.022_bib11","first-page":"4349","article-title":"Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines","volume":"58","author":"Mackey","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.biomaterials.2018.10.022_bib12","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1124\/dmd.108.020925","article-title":"Gemcitabine pharmacogenomics: deoxycytidine kinase and cytidylate kinase gene resequencing and functional genomics","volume":"36","author":"Kocabas","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.biomaterials.2018.10.022_bib13","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1634\/theoncologist.2007-0215","article-title":"Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy","volume":"13","author":"Veltkamp","year":"2008","journal-title":"Oncol."},{"key":"10.1016\/j.biomaterials.2018.10.022_bib14","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1038\/mt.2013.120","article-title":"Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC","volume":"21","author":"Zhang","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biomaterials.2018.10.022_bib15","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1016\/j.biomaterials.2013.01.063","article-title":"Systemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapy","volume":"34","author":"Zhang","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.biomaterials.2018.10.022_bib16","first-page":"1021","article-title":"Myeloid-derived suppressor cells in malignant melanoma","volume":"12","author":"Umansky","year":"2014","journal-title":"J. Dtsch Dermatol. Ges."},{"key":"10.1016\/j.biomaterials.2018.10.022_bib17","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jconrel.2011.10.020","article-title":"Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor","volume":"158","author":"Li","year":"2012","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.biomaterials.2018.10.022_bib18","doi-asserted-by":"crossref","first-page":"37637","DOI":"10.1021\/acsami.7b13416","article-title":"Sulfur-Doped graphene-based immunological biosensing platform for multianalysis of cancer biomarkers","volume":"9","author":"Ren","year":"2017","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.biomaterials.2018.10.022_bib19","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.bios.2017.03.064","article-title":"Increased electrocatalyzed performance through high content potassium doped graphene matrix and aptamer tri infinite amplification labels strategy: highly sensitive for matrix metalloproteinases-2 detection","volume":"94","author":"Ren","year":"2017","journal-title":"Biosens. Bioelectron."},{"key":"10.1016\/j.biomaterials.2018.10.022_bib20","doi-asserted-by":"crossref","first-page":"8459","DOI":"10.1016\/j.biomaterials.2013.07.050","article-title":"Combinational delivery of c-myc siRNA and nucleoside analogs in a single, synthetic nanocarrier for targeted cancer therapy","volume":"34","author":"Zhang","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.biomaterials.2018.10.022_bib21","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41467-017-02251-3","article-title":"Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity","volume":"9","author":"Zhang","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biomaterials.2018.10.022_bib22","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/(SICI)1520-6017(200003)89:3<355::AID-JPS7>3.0.CO;2-H","article-title":"Lyophilization of cationic lipid-protamine-DNA (LPD) complexes","volume":"89","author":"Li","year":"2000","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.biomaterials.2018.10.022_bib23","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3389\/fonc.2014.00349","article-title":"Myeloid-derived suppressor cells as therapeutic target in hematological malignancies","volume":"4","author":"De Veirman","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biomaterials.2018.10.022_bib24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.canlet.2013.01.010","article-title":"Anti-apoptotic proteins on guard of melanoma cell survival","volume":"331","author":"Hartman","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biomaterials.2018.10.022_bib25","first-page":"3","article-title":"Gemcitabine: metabolism, mechanisms of action, and self-potentiation","volume":"22","author":"Plunkett","year":"1995","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.biomaterials.2018.10.022_bib26","doi-asserted-by":"crossref","first-page":"e0196040","DOI":"10.1371\/journal.pone.0196040","article-title":"Tracking the fate of adoptively transferred myeloid-derived suppressor cells in the primary breast tumor microenvironment","volume":"13","author":"Sceneay","year":"2018","journal-title":"PloS One"},{"key":"10.1016\/j.biomaterials.2018.10.022_bib27","doi-asserted-by":"crossref","first-page":"5791","DOI":"10.4049\/jimmunol.181.8.5791","article-title":"Subsets of myeloid-derived suppressor cells in tumor-bearing mice","volume":"181","author":"Youn","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.biomaterials.2018.10.022_bib28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1757-2215-7-19","article-title":"A high M1\/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients","volume":"7","author":"Zhang","year":"2014","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.biomaterials.2018.10.022_bib29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.it.2010.10.002","article-title":"Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function","volume":"32","author":"Condamine","year":"2011","journal-title":"Trends Immunol."},{"key":"10.1016\/j.biomaterials.2018.10.022_bib30","doi-asserted-by":"crossref","first-page":"11676","DOI":"10.1074\/jbc.M112.441402","article-title":"Tumor STAT1 transcription factor activity enhances breast tumor growth and immune suppression mediated by myeloid-derived suppressor cells","volume":"288","author":"Hix","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biomaterials.2018.10.022_bib31","article-title":"The role of myeloid-derived suppressor cells (MDSC) in cancer progression","volume":"4","author":"Umansky","year":"2016","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.biomaterials.2018.10.022_bib32","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1084\/jem.20080132","article-title":"Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein","volume":"205","author":"Cheng","year":"2008","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.biomaterials.2018.10.022_bib33","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/ATVBAHA.113.301453","article-title":"Transcriptional control of macrophage polarization","volume":"33","author":"Tugal","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.biomaterials.2018.10.022_bib34","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3389\/fimmu.2014.00614","article-title":"Molecular mechanisms that influence the macrophage m1-m2 polarization balance","volume":"5","author":"Wang","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biomaterials.2018.10.022_bib35","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1182\/blood-2011-02-339911","article-title":"Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology","volume":"119","author":"Pello","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.biomaterials.2018.10.022_bib36","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.bbadis.2017.01.006","article-title":"IL-6 promotes M2 macrophage polarization by modulating purinergic signaling and regulates the lethal release of nitric oxide during Trypanosoma cruzi infection","volume":"1863","author":"Sanmarco","year":"2017","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.biomaterials.2018.10.022_bib37","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.4049\/jimmunol.1401572","article-title":"The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity","volume":"193","author":"Ostrand-Rosenberg","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.biomaterials.2018.10.022_bib38","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1084\/jem.20131916","article-title":"PD-L1 is a novel direct target of HIF-1 alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation","volume":"211","author":"Noman","year":"2014","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.biomaterials.2018.10.022_bib39","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1126\/science.aac9935","article-title":"MYC regulates the antitumor immune response through CD47 and PD-L1","volume":"352","author":"Casey","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.biomaterials.2018.10.022_bib40","doi-asserted-by":"crossref","first-page":"e112717","DOI":"10.1371\/journal.pone.0112717","article-title":"Tumor induced hepatic myeloid derived suppressor cells can cause moderate liver damage","volume":"9","author":"Eggert","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.biomaterials.2018.10.022_bib41","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.ejca.2013.11.028","article-title":"Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy","volume":"50","author":"Lee","year":"2014","journal-title":"Eur. J. Canc."},{"key":"10.1016\/j.biomaterials.2018.10.022_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00280-016-3003-0","article-title":"Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective","volume":"78","author":"Ciccolini","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.biomaterials.2018.10.022_bib43","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jconrel.2013.06.009","article-title":"Turning an antiviral into an anticancer drug: nanoparticle delivery of acyclovir monophosphate","volume":"170","author":"Yao","year":"2013","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.biomaterials.2018.10.022_bib44","doi-asserted-by":"crossref","first-page":"18542","DOI":"10.1039\/C5NR04509F","article-title":"Theranostic etoposide phosphate\/indium nanoparticles for cancer therapy and imaging","volume":"7","author":"Srinivas","year":"2015","journal-title":"Nanoscale"},{"key":"10.1016\/j.biomaterials.2018.10.022_bib45","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1006\/jcis.1996.4647","article-title":"J. Synthesis of copper nanoparticles in nonionic water-in-oil microemulsions","volume":"186","author":"Qi","year":"1997","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.biomaterials.2018.10.022_bib46","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1016\/j.bbamem.2009.06.022","article-title":"Nanoparticles evading the reticuloendothelial system: role of the supported bilayer","volume":"1788","author":"Li","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.biomaterials.2018.10.022_bib47","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/mt.2012.79","article-title":"In vivo gene delivery by nonviral vectors: overcoming hurdles?","volume":"20","author":"Zhang","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biomaterials.2018.10.022_bib48","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.jconrel.2009.11.008","article-title":"Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery","volume":"142","author":"Li","year":"2010","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.biomaterials.2018.10.022_bib49","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1021\/bi9602019","article-title":"Mechanism of DNA release from cationic liposome\/DNA complexes used in cell transfection","volume":"35","author":"Xu","year":"1996","journal-title":"Biochemistry"},{"issue":"Suppl 5","key":"10.1016\/j.biomaterials.2018.10.022_bib50","doi-asserted-by":"crossref","first-page":"v7","DOI":"10.1093\/annonc\/mdj941","article-title":"Cellular pharmacology of gemcitabine","volume":"17","author":"Mini","year":"2006","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biomaterials.2018.10.022_bib51","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/cdd.2013.67","article-title":"Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer","volume":"21","author":"Bracci","year":"2014","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.biomaterials.2018.10.022_bib52","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1158\/2326-6066.CIR-15-0064","article-title":"The interplay of immunotherapy and chemotherapy: harnessing potential synergies","volume":"3","author":"Emens","year":"2015","journal-title":"Canc. Immunol. Res."},{"key":"10.1016\/j.biomaterials.2018.10.022_bib53","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.4049\/jimmunol.170.10.4905","article-title":"Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells","volume":"170","author":"Nowak","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.biomaterials.2018.10.022_bib54","doi-asserted-by":"crossref","first-page":"5821","DOI":"10.4049\/jimmunol.1400404","article-title":"Regulatory T cells and myeloid-derived suppressor cells in the tumor microenvironment undergo Fas-dependent cell death during IL-2\/alphaCD40 therapy","volume":"192","author":"Weiss","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.biomaterials.2018.10.022_bib55","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.18632\/oncotarget.13978","article-title":"IL-17A weakens the antitumor immunity by inhibiting apoptosis of MDSCs in Lewis lung carcinoma bearing mice","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.biomaterials.2018.10.022_bib56","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/imm.12036","article-title":"The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells","volume":"138","author":"Lindau","year":"2013","journal-title":"Immunology"},{"key":"10.1016\/j.biomaterials.2018.10.022_bib57","doi-asserted-by":"crossref","first-page":"4666","DOI":"10.4049\/jimmunol.181.7.4666","article-title":"Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells","volume":"181","author":"Sinha","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.biomaterials.2018.10.022_bib58","doi-asserted-by":"crossref","first-page":"42698","DOI":"10.18632\/oncotarget.8311","article-title":"Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy","volume":"7","author":"Dufait","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.biomaterials.2018.10.022_bib59","doi-asserted-by":"crossref","first-page":"11345","DOI":"10.18632\/oncotarget.2489","article-title":"Interactome analysis of myeloid-derived suppressor cells in murine models of colon and breast cancer","volume":"5","author":"Aliper","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.biomaterials.2018.10.022_bib60","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3389\/fimmu.2018.00398","article-title":"Targeting myeloid-derived suppressor cells to bypass tumor-induced immunosuppression","volume":"9","author":"Fleming","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biomaterials.2018.10.022_bib61","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T cells","volume":"206","author":"Francisco","year":"2009","journal-title":"J. Exp. Med."}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961218307361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961218307361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:43:57Z","timestamp":1788983037000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961218307361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":61,"alternative-id":["S0142961218307361"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2018.10.022","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gemcitabine nanoparticles promote antitumor immunity against melanoma","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2018.10.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}